Marvel Biosciences Corp.
MBCOF
$0.10
$0.000.63%
OTC PK
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.75% | -1.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.78% | 101.99% | |||
| Operating Income | 48.78% | -101.99% | |||
| Income Before Tax | 71.53% | -378.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 71.53% | -378.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 71.53% | -378.35% | |||
| EBIT | 48.78% | -101.99% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 73.17% | -320.51% | |||
| Normalized Basic EPS | 72.55% | -325.00% | |||
| EPS Diluted | 73.17% | -320.51% | |||
| Normalized Diluted EPS | 72.55% | -325.00% | |||
| Average Basic Shares Outstanding | 4.92% | 13.34% | |||
| Average Diluted Shares Outstanding | 4.92% | 13.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||